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In vitro evidence for senescent multinucleated
melanocytes as a source for tumor-initiating cells
C Leikam1, AL Hufnagel1, C Otto2, DJ Murphy3, B Mühling2, S Kneitz1, I Nanda4, M Schmid4, TU Wagner1, S Haferkamp5, E-B Bröcker6,
M Schartl1,7 and S Meierjohann*,1,7
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle arrest frequently
characterized by a bi- or multinuclear phenotype that is considered as a barrier to cancer progression. However, the long-sustained
conviction that senescence is a truly irreversible process has recently been challenged. Still, it is not known whether cells driven
into OIS can progress to cancer and thereby pose a potential threat. Here, we show that prolonged expression of the melanoma
oncogene N-RAS61K in pigment cells overcomes OIS by triggering the emergence of tumor-initiating mononucleated stem-like cells
from senescent cells. This progeny is dedifferentiated, highly proliferative, anoikis-resistant and induces fast growing, metastatic
tumors. Our data describe that differentiated cells, which are driven into senescence by an oncogene, use this senescence state as
trigger for tumor transformation, giving rise to highly aggressive tumor-initiating cells. These observations provide the first
experimental in vitro evidence for the evasion of OIS on the cellular level and ensuing transformation.
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Cellular senescence is characterized by cell-cycle arrest and
alterations in cell shape and metabolism, and can be triggered
either by the sequential loss of telomeres or by numerous
forms of cellular stress, for example, UV irradiation, oxidative
stress or aberrant oncogenic signaling (premature senes-
cence). In particular, oncogene-induced senescence (OIS),
driven for example by activated RAS or BRAF, is an anti-
cancer protection mechanism that prevents tumor generation
despite the presence of oncogenic mutations. For instance,
human nevi exhibit enhanced MAPK signaling caused by
activating mutations in B-RAF or N-RAS. They display
classical characteristics of senescence,1 and remain benign
in the large majority of cases. However, nevi are also
supposed to give rise to a quarter of all melanomas.2
Along the same lines, oncogenic RAS clearly triggers OIS in
different cell types in vivo,3–6 but activated RAS is detected in
up to 30% of human cancers.7,8 This indicates that senes-
cence bypass is a key feature of cancer development. The fact
that many premalignant tissues with tumorigenic potential
display features of senescence has led to the concept that OIS
precedes transformation, and tumors arise from senescent
tissue.1,5,6,9 However, as OIS was long considered to be
irreversible, it was not clear how this transformation process
can take place. Recently, there has been accumulating
evidence that OIS can be reversed under certain circum-
stances on the cellular level. Specifically, H-RAS12V induces
senescence in fibroblasts, which is caused by ribonucleotide
reductase (RRM2) suppression and accompanying dNTP
reduction.10 Interestingly, the forced re-expression of RRM2
is able to overcome senescence. Still, is not known whether a
senescent primary cell might give rise to cancer. While the
later steps of tumor progression are fairly well understood,
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early events in tumorigenesis such as the transition of a benign
senescent lesion to a tumor are still enigmatic.
Here, we reveal that long-term NRAS61K activation in
melanocytes triggers a strong senescent phenotype char-
acterized by multinucleation, which then is followed by the
post-senescence generation of tumor-initiating cells with stem
cell-like properties. The results demonstrate that senescence
in melanocytes can be overcome on the cellular level and can
also be a source for malignant cancer cells.
Results
Multinucleated cells are frequently found in human
nevi. When we analyzed randomly chosen sections of
paraffin-embedded acquired melanocytic nevi, we found
multinucleated nevus cells in 13/28 samples (46%). In most
cases, samples contained few multinucleated cells, amounting
to less than 1% of the nevus cell population, although
some nevi showed a higher abundance of these abnormal
cells, reaching up to 23% (Figure 1a). In vitro, such bi- or
multinucleation of non-transformed cells occurs under condi-
tions of senescence.11–14 The strong nuclear disturbance
induces an efficient cell-cycle block in non-transformed cells.
The causes leading to multinucleation can be manifold and
encompass UV damage, elevated levels of reactive oxygen
species (ROS) and oncogenic stress, for example, by the
melanoma oncogene N-RAS61K that efficiently induces OIS
in melanocytes.11,12,14,15
To investigate the dual role of oncogenic RAS as senes-
cence inducer and tumor driver, we overexpressed N-RAS61K
in a vector with simultaneous GFP coexpression in normal
human epidermal melanocytes (NHEM). As expected, we
observed an N-RAS61K –induced stop in cell-cycle prolifera-
tion (Supplementary Figure S1) as well as the induction of bi-
andmultinucleation by N-RAS61K (Figures 1b and c). Although
OIS is widely considered to be a tumor-suppressive process,
we found that cultivation of oncogene-expressing primary
human melanocytes for more than 3 weeks led to the
generation of proliferating cell clones (Figures 1d and e).
The cells overgrew the non-transfected cells, and clusters of
viable cells were found in the supernatant, indicating anoikis
resistance (Figures 1f and g). These cells lacked melanocyte
differentiation markers such as DCT and TYRP1 (Figure 1h).
Multinucleated melanocytes give rise to proliferation-
competent progeny. To follow the fate of multinucleated
cells after longterm N-RAS61K stimulation, we used murine
instead of human melanocytes, as replicative exhaustion can
Figure 1 Nevus melanocytes and senescent melanocytes are frequently
multinucleated. (a) Left: Acquired cutaneous nevus, stained with periodic acid Schiff
(PAS) reagent to visualize the membranes. PAS was used for the detection of
mucosubstances including glykoproteins and glykolipids that are characteristic for
cellular membranes. The dense, dark stained lines between the cells demarcate
the membranes. Right: Magnification of the highlighted region. Some of the
multinucleated cells are marked by white circles. White scale bar: 25 μm, black scale
bar: 5 μm. (b and c) Expression of N-RAS61K using the plasmid pCDH-CMV-
N-RAS61K-EF1-copGFP, inducing flat and binuclear appearance shortly after
introduction of the plasmid. The arrows in (b and c) indicate two different nuclei in
single cells. (d and e) After 3 weeks of cultivation, GFP/N-RAS61K-positive cells
started to form colonies, which overgrew the cell culture. (f) In addition, detached cell
clusters were found in the supernatant. The unfocused cells in the background
represent the attached, non-transfected cells at the bottom of the culture dish. (g) The
detached cell clusters could be replated, demonstrating anoikis resistance. Scale
bars, 100 μm. Similar observations were made in three independent experiments.
(h) RT-PCR analysis (28 cycles) of TYRP1 and DCT expression in NHEM control
cells and two N-RAS61K-transgenic NHEM cell clones, which grew out after several
weeks of cultivation and developed anoikis resistance. The RT-PCR is representative
of three independent biological replicates. Ribosomal S14 was used as a reference
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be prevented in these cells under well-established in vitro
culture conditions by the addition of tetradecanoyl-12,13-
phorbolacetate (TPA).16 We have shown previously that
N-RAS61K expression in melan-a murine melanocytes similar
to NHEM cells leads to a multinucleated phenotype. This is
caused by N-RAS induction of ROS and is accompanied by
p53 signaling and senescence-associated β-galactosidase
(SA-β-Gal) expression.11 We used a doxycycline-inducible
N-RAS61K vector to drive long-term expression in melano-
cytes for extended time periods. After 14 days of doxycycline
treatment, a large fraction of cells had become senescent, as
demonstrated by their multinucleated phenotype and SA-β-
Gal staining, which mostly correlated (Figure 2a, middle
panel). In addition, proliferation was impeded, comparable to
control cells which are not expected to proliferate in the
absence of TPA (see Figure 5e: ‘ctrl’ and ‘N-RAS61K’).
Importantly, the overall levels of oncogenic N-RAS were only
slightly enhanced (Supplementary Figure S2A), thus showing
that this phenotype is visible under conditions which mimic
the in vivo situation. N-RAS61K expression went along with
activation of the MAPK and PI3K pathways, as seen by
enhanced P-ERK1/2 and P-AKT levels (Supplementary
Figure S2B). The N-RAS61K mediated senescence is
characterized by activation of the p53 pathway, as indicated
by p19-ARF induction as well as enhanced DNA damage
signaling, which was visible as enhanced γ-H2AX and P-p53
levels. p21 levels were barely altered and p16 levels were not
visible (Supplementary Figure S2B). After 2–3 weeks, we
observed that multinucleated cells were sometimes sur-
rounded by small mononucleated cells (Supplementary
Figure S2C). Furthermore, after 3–4 weeks of N-RAS61K
expression, proliferating cells appeared that overgrew the cell
culture and formed three-dimensional cellular aggregates
typical for transformed cells in vitro (Figure 2a, lower panel).
Concurrently, we noted the appearance of viable, detached
cells in the culture supernatant. Replating of such floating
cells was followed by reattachment before they again gave
rise to detached cells. We termed these cells ‘N-RAS61K-AR’
(for ‘anoikis resistant’).
To trace the origin of the proliferating cells, we conducted
time lapsemovies of multinucleated N-RAS61K cells after long-
term oncogene stimulation. To resolve single cells, we
transfected the N-RAS61K cells with a plasmid, which allows
to separately visualize membranes (red-purple) and nucleus
(green). We recorded several highly multinucleated cells
performing asynchronous cytokinesis, as for example shown
in Figure 2b. The figure depicts two adjacent multinucleated
cells with cytokinesis occurring in the cell on the right
(Figure 2b, Supplementary Movie 1). Strikingly, this asynchro-
nous cytokinesis resulted in the budding of small, mono-
nuclear, viable cells that underwent further cell divisions
(Figures 2c and d, Supplementary Movies S2A and B). The
parental cells remained multinuclear and persisted throughout
the experiments.
To compare the features of naïve N-RAS61K cells,
N-RAS61K-AR cells that arise after senescence induction,
and melan-a control cells (transfected with pTRE2hyg control
vector, but simply termed ‘melan-a’ hereafter) we monitored
proliferation under different cell culture conditions. N-RAS61K-
AR cells but not melan-a or N-RAS61K cells grew efficiently in
the absence of TPA (Figure 2e) and under growth factor-
deprived conditions (Supplementary Figures S3A and B).
The unexpected proliferation behavior of N-RAS61K-AR
cells derived from senescent cell cultures was further
confirmed by their capacity to efficiently form soft agar
colonies (Figure 2f). Furthermore, when we analyzed four
different N-RAS61K-AR cell clones, we noted several
chromosomal aberrations, indicating that the cells had
undergone a phase of genetic instability (Supplementary
Table S1).
N-RAS61K-AR cells are tumorigenic and dedifferentiated.
To analyze tumorigenicity in vivo, melan-a, N-RAS61K and
N-RAS61K-AR cells were injected subcutaneously into nude
mice. Melan-a and N-RAS61K cells gave rise to subcuta-
neous, pigmented, nevus-like structures (Figures 3a and b,
Supplementary Figures S4A and B, Supplementary Table S2).
N-RAS61K-AR cells, however, formed large tumors at all
injection sites after approximately 10 days (Figures 3c, d–g,
Supplementary Table S2). Strikingly, tumor formation
occurred in the absence of doxycycline. Mitotic figures were
abundant in tumor sections (Figure 3e), and staining of the
S-phase marker Ki67 as well as the mitosis marker phospho-
histone H3 (Ser10) was readily detectable in tumors, but not
in nevus-like structures of control mice (Figures 3h and i,
Supplementary Figures S4C and D), strongly indicating a
high in-vivo proliferation potential of N-RAS61K-AR cells. The
mice had to be killed after 4 weeks due to the high tumor
load. Notably, by this time, the primary tumor had already
metastasized to the lung (Figure 3f).
To gain insight into the process leading to the generation of
the highly aggressive N-RAS61K-AR cells from a previously
senescent cell culture, expression profiling of N-RAS61K cells
at different times of doxycycline stimulation and of N-RAS61K-
AR cells was performed. We found the expression of
melanocyte differentiation markers to be highly regulated in
response to N-RAS61K expression (Figures 4a and b).
Concurrent with senescence progression, differentiation
markers, such as Tyrp1, Mlana, Dct, Sox10 and Mitf, were
strongly induced after 14 days. However, expression of most
differentiation markers decreased after 28 days of N-RAS61K
induction and in N-RAS61K-AR cells. In contrast, Mitf levels
were still higher in N-RAS61K-AR when compared with the 6-
day sample. It is known that a certain level of MITF is similarly
maintained in human melanoma, consistent with its role for
melanocyte and melanoma proliferation and survival.17 Con-
comitant with the decrease of differentiation genes, numerous
genes, which are typical for neuronal tissues or the neural
crest, were induced (Figures 4c and d). Many of these genes
were still expressed in N-RAS61K-AR cells. During embryonic
development, melanocytes arise from the neural crest lineage.
Re-expression of embryonic or neuronal genes is associated
with a stem cell-like phenotype and is a hallmark of aggressive
human melanomas.18,19 To test whether the N-RAS61K-AR
cells display features of stem-like cells, we looked at the
expression of embryonal and stem cell markers. Interestingly,
Pdpn and Nanog were among the genes whose expression
was markedly increased in N-RAS61K-AR cells (Figure 4e). In
particular, NANOG is considered as a master transcription
factor for the maintenance of the undifferentiated state and
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Figure 2 Multinuclear cells give rise to small proliferative cells. (a) Phase-contrast (PH) images of melan-a control cells and N-RAS61K cells after 14, 21 and 28 days of
doxycycline treatment (1 μg/ml) and the corresponding brightfield images of SA-β-galactosidase-stained melan-a and N-RAS61K cells after 14 days. Scale bars, 100 μm. Please
note that melan-a cells do not display signs of senescence in the absence of N-RAS61K. Similar observations were made in45 independent experiments. (b) N-RAS61K cells
were transiently transfected with pBabe-MN (EF1a-red membrane and green nucleus)-2APuro before being plated onto glass coverslips. Upon 16 days of doxycycline treatment,
cells were monitored for 17 h. Time points are indicated. Scale bars, 50 μm. (c and d) N -RAS61K cells were transiently transfected with pBabe-puro-H2-eGFP before being plated
onto glass coverslips. Upon 27 days of doxycycline treatment, cells were monitored for 28 h at 100-fold magnification and pictures were taken every 15 min. Scale bars, 50 μm.
(c) GFP fluorescence of the cells. (d) As in (c), but merge of phase contrast and GFP. Time points are indicated. Arrows pinpoint the budding and dividing cell. (e) Proliferation of
melan-a, N-RAS61K and N-RAS61K-AR cells in DMEM containing 10% FCS, antibiotics and, where indicated, tetradecanoyl-12,13-phorbolacetate (TPA). (f) Soft agar growth
assay of N-RAS61K and N-RAS61K-AR cells, cultivated for 14 days in DMEM containing 10% FCS and antibiotics. Scale bars, 100 μm. *Po0.05; **Po0.01
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cellular self-renewal. Using a NANOG-driven GFP reporter,20
we found a large fraction of N-RAS61K-AR cells with activated
Nanog promoter activity, which was not observed in N-RAS61K
cells (Figure 4f). N-RAS61K-AR cells also displayed a
reduction of cytoplasmic volume and consequently a higher
nuclear/cytoplasmic ratio compared with N-RAS61K cells
(Figure 4g, Supplementary Movie S3), which is a morpholo-
gical feature of stem-like and dedifferentiated cells.
Further analysis of the genes distinguishing N-RAS61K-AR
cells from all other samples led to two prominent groups:
(1) positive regulation of proliferation and (2) meiosis genes
(Supplementary Figure S5). The group ‘positive regulation of
proliferation’ included numerous genes encoding growth
factors (e.g., Kitl, Vegfa, Hbegf, Btc and Areg) and growth
factor receptors (Pdgfra, Flt1) as well as enzymes involved in
generation and transmission of growth-promoting signaling
molecules (Ptgs2, Fabp4) (Supplementary Figure S5A and B).
These data suggest that the AR cells are able to provide a
number of autocrine signals, which sustain cell growth even
under growth-restricting conditions such as starvation or
withdrawal of TPA (as reported above). Indeed, ERK1/2
activity, which efficiently transmits growth-promoting signals in
melanocytes, was increased in N-RAS61K-AR cells and
reached higher levels than in doxycycline-stimulated
N-RAS61K cells (Supplementary Figure S5C).
Among the genes included in the meiosis signature
(Supplementary Figures S5D and E), Spo11 is also known
as cancer/testis gene21 and it displays copy number gains in
different cancer types such as colorectal and gastric cancer
(www.oncomine.org). Cyp26b1 is involved in retinoic acid
metabolism and has a role in neural crest-derived tissue
development.22 Meiosis-related genes are often upregulated
Figure 3 Long-term N-RAS61K activation leads to melanocyte senescence followed by anoikis resistance and tumorigenicity in vivo. (a and b) Macroscopic appearance of
subcutaneous tissue 10 weeks after injection of N-RAS61K cells into nude mice. Where indicated, 2 mg/ml doxycycline (Dox) was added to the drinking water of the mice.
(c) Macroscopic view of tumor development after subcutaneous injection of N-RAS61K -AR cells into nude mice. (d–f) Hematoxylin/eosin stained tissue sections. In (d and e),
N-RAS61K -AR-derived tumors are displayed (d: scale bar, 50 μm; e: scale bar, 20 μm). The arrows in (e) indicate mitotic figures. (f) Lung metastasis in a N-RAS61K-AR-injected
nude mouse. The inlay shows a magnification of the metastasis. Scale bar, 500 μm. (g) Time-dependent development of subcutaneous tumors in N-RAS61K-AR-injected nude
mice. The different colors represent the single tumors from both flanks of each mice. (h) Hoechst and Ki67 staining and (i) Hoechst and P-H3 staining of a tumor section from
N-RAS61K-AR-injected mice visualizing strong mitotic activity throughout the tumor. Scale bars, 100 μm
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in melanoma cells that are particularly prone to so-called
‘meiomitosis’, describing the partial expression of meiosis
machinery in mitotic cells.23 Taken together, the expression
profile provides evidence for melanocyte dedifferentiation,
which is a typical feature of invasive melanoma cells,24–26
upon long-term N-RAS61K activation and reveals the
expression of stem-like and meiosis-associated genes in
N-RAS61K-AR cells.
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The development of anoikis resistance is dependent on
prior senescence. To verify that the cell population that
gives rise to anoikis-resistant cells is truly senescent, we
made use of the fact that p53 is strongly induced during
senescence in N-RAS61K-expressing multinucleated
melanocytes.11 N-RAS61K cells were transiently transfected
with the p53-specific GFP reporter plasmid. The pGreenFire-
p53 plasmid is a lentiviral reporter vector containing a p53
responsive element, thus directly displaying p53 activity. A
strong GFP signal was visible in senescent multinucleated
N-RAS61K cells, but not in control melan-a cells (Figure 5a).
To obtain a 100% senescent melanocyte population,
N-RAS61K cells were strictly sorted for high GFP intensity
and large cell size by flow cytometry (Figure 5b) and were
then seeded at low density. These isolated multinucleated
cells were termed N-RAS61K-s (s for ‘sorted’). They were able
to repopulate the culture dish with small cells after 3 weeks
(Figure 5c). Furthermore, anoikis-resistant cells appeared
after the cells became confluent (Figure 5d), confirming that
they originate from the senescent cells. The anoikis-resistant
cells were harvested from the supernatant (‘N-RAS61K-s-
AR’), and their growth was monitored in comparison with
N-RAS61K- and N-RAS61K-s cells. As expected, N-RAS61K-s
and N-RAS61K-s-AR, but not the parental N-RAS61K cells
displayed a strong proliferation potential both in the absence
of TPA and in growth factor-reduced serum (Figure 5e). In
addition, they were able to efficiently grow in soft agar
(Figure 5f).
To test the effect of an independent OIS inducer, we used
the melanoma-associated receptor tyrosine kinase Xmrk, an
EGFR family protein that strongly drives MAPK and PI3K
pathways and induces a senescence phenotype with accom-
panying proliferation inhibition similar to N-RAS61K.11,27 Again,
senescence of oncogene-expressing melan-a cells was
followed by the generation of three-dimensionally growing
cells and anoikis resistance (Figure 6a). Similar to the
observation for N-RAS61K-AR cells, Nanog promoter activity
was also induced by this oncogene (Figure 6b).
Senescence induced by oncogenes is not immediately
executed after oncogene activation, but only comes into action
after a previous proliferation boost caused by strong, growth-
promoting signals.28 To determine whether a proliferation
stimulus per se leads to the observed dedifferentiation and
anoikis resistance, we cultivated the parental cell line melan-a
for long time periods in the presence of the growth stimulus
TPA, an efficient activator of PKC and the MAPK pathway.
Apart from the addition of TPA, melan-a cells underwent the
same treatment as N-RAS61K cells. After TPA-treated melan-a
cells had reached confluency, pigmentation increased
(Figure 6c). Upon 28 days of treatment, we could neither
observe viable, detached melan-a cells in the supernatant nor
the three-dimensional cell colonies we observed in N-RAS61K
cells (Figures 6c and d). Furthermore, these cells showed the
induction neither of the pluripotency markers Pdpn andNanog
nor of the male meiosis marker Spo11, whereas the
melanocyte markers Mlana, Tyrp1 and Dct were generally
upregulated (though the data only reached significance in
case of Mlana) (Figure 6e). Thus, the mere induction of
proliferation is not sufficient to allow the generation of
AR-cells.
Anoikis resistance does not depend on oncogene
expression levels. To investigate whether a change in
N-RAS61K expression could affect senescence phenotype
or anoikis resistance, we generated an independent
N-RAS61K transgenic cell line, which allows very fine-tuned
expression induction accompanied by inducible GFP fluor-
escence. We applied 10, 25, 100 and 1000 ng/ml doxycycline
to these cells and followed their behavior over time. From
25 ng/ml on, expression was visible on GFP level
(Supplementary Figure S6A) as well as NRAS RNA level
(Supplementary Figure S6B). At 0 and 10 ng/ml, no GFP or
RNA signals were detected. Interestingly, senescence was
only visible in those cells, which were treated with doxycy-
cline concentrations starting from 25 ng/ml (Supplementary
Figure S7A). In accordance, all these cells developed anoikis
resistance (Supplementary Figure S7B) and dedifferentiation
as well as upregulation of the AR marker genes Pdpn and
Nefl (Supplementary Figures S7C and E). Although a slight
downregulation of differentiation genes was even detected
after treatment with 10 ng/ml doxycycline, the stemness gene
Pdpn and the neuronal gene Nefl were barely changed under
these conditions. These data show that the degree of
N-RAS61K expression is not important for senescence and
anoikis resistance once a critical, but small threshold level is
reached.
Signaling pathways involved in senescence-dependent
anoikis resistance. Next, we analyzed the pathways
necessary for mediating the generation of N-RAS61K-AR
cells by using inhibitors, which were added to the cells
at the start of the experiment. We first blocked the MAPK
and PI3K pathways, which are both direct effectors down-
stream of N-RAS61K, using the small molecule inhibitors
PD184352 or LY294002, respectively. MEK inhibitor
PD184352, but not PI3K inhibitor LY294002 prevented the
Figure 4 Long-term N-RAS61K expression diminishes melanocyte marker expression and increases neuronal gene expression and pluripotency features. (a) Heatplot
displaying the RNA expression of melanocyte differentiation markers in N-RAS61K cells stimulated with doxycycline for 6, 14 and 28 days and in N-RAS61K-AR cells.
(b) Confirmation of differential gene expression by real-time PCR using primers directed against Tyrp1,Mlana, Dct, Sox10 andMitf. (c) Heatplot displaying the RNA expression of
neuronal genes in the same samples as described in (a). (d) Real-time analysis showing differential expression of Nefl and Smarca. For (a and c), the values are color coded
using a green–red scale, where green indicates low expression and red indicates high expression. (e) Real-time PCR analysis of Pdpn expression (upper panel) and RT-PCR
analysis of Nanog expression (40 cycles, lower panel) in N-RAS61K cells stimulated with doxycycline for 6, 14 and 28 days and in N-RAS61K-AR cells. Hprt served as a control. (f)
Nanog-driven GFP expression in N-RAS61K and N-RAS61K-AR cells, transiently transfected with the PL-SIN-EOS-S(4+)-eGFP vector. Scale bars, 100 μm. (g) Determination of
the nuclear/cytoplasmic ratio of N-RAS61K and N-RAS61K–AR cells. Left: Confocal images of N-RAS61K and N-RAS61K-AR cells. Arrows, 50 μm. Right: Averaged cellular, nuclear
or cytoplamic volume of N-RAS61K and N-RAS61K-AR cells upon generation of confocal stacks (see Supplementary Movie S3). Compartment volumes were determined using
Volocity v4 software, P= 0.0076 (cell), P= 0.0052 (cytoplasm); n= 6. *Po0.05; **Po0.01, ***Po0.001
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formation of multinucleated cells (Supplementary Figure S8A).
In both cases, the cells were incapable of producing
anoikis-resistant progeny (Figure 7a). Similar results were
obtained with a different PI3K inhibitor (GDC-0941,
Supplementary Figure S8C).
ROS have an important role in melanoma development and
pro-tumorigenic signaling.29–31 RAS activation leads to the
induction of NADPH oxidase isoforms (Figure 7b, upper image
and Weyemi et al.32). This is accompanied by the generation
of ROS.32,33 Accordingly, activation of oncogenic N-RAS in
melan-a cells causes DNA damage and p53 activation, as
described above. To elucidate the role of DNA damage and
senescence induction in N-RAS61K-AR development, we
applied the antioxidant glutathione ethyl ester or inhibited
NADPH oxidase (diphenyle iodonium, DPI), ATM (caffeine) or
p53 (pifithrine). DPI, caffeine and pifithrine, but not the
glutathione component, were able to prevent the generation
of multinucleated (Supplementary Figures S8A and B) and
anoikis-resistant cells (Figures 7a and b, lower image),
consistent with the involvement of DNA damage and
senescence induction in this process. To test whether the
inhibitors that prevent anoikis resistance are only involved in
Figure 5 Only senescent NRAS61K cells give rise to anoikis-resistant progeny. (a) Melan-a control cells (upper images) and N-RAS61K cells (lower images) were cultivated in
the presence of doxycycline (Dox) before they were transiently transfected with the pGreenFire-p53 reporter plasmid. Note the strong GFP staining for the multinucleated
N-RAS61K melanocytes. Scale bars, 75 μm. (b) After 1 week of doxycycline stimulation, p53-GFP-transfected N-RAS61K cells were sorted for large cell size (as characteristic for
the senescent multinucleated cells) and strong GFP positivity. (c) Appearance of cells 2 weeks after sorting (left) and 1 week later (right). Scale bars, 35 μm. (d) After 6 weeks,
supernatant from sorted cells was transferred to a new dish and was allowed to attach overnight, before a crystal violet staining was performed. Please note that due to the low
initial cell density in the dishes, the amount of cells in the supernatant is much lower than in previous figures, thus giving only rise to weak crystal violet staining. Arrows indicate
the presence of some exemplary cell colonies (left). A magnification shows the accumulation of many cells to one colony, suggesting that the cells that gave rise to the colony were
present as spheroid in the cell culture supernatant (right). Scale bar, 50 μm. (e) Proliferation of melan-a (ctrl.), and unsorted N-RAS61K cells (N-RAS61K) as well as N-RAS61K cells
sorted for GFP and large cell size (N-RAS61K-s) and corresponding anoikis-resistant cells from the supernatant (N-RAS61K-s-AR). Cells were either kept in starving medium (10%
dialyzed FCS) containing Dox or in normal culture medium without TPA, as indicated. Asterisks indicate statistical significance of N-RAS61K-s and N-RAS61K-s-AR cells compared
with N-RAS61K cells. *Po0.05; **Po0.01, ***Po0.001; n= 3. (f) Soft agar growth assay of N-RAS61K, N-RAS61K-s and N-RAS61K-s-AR cells, cultivated for 14 days in DMEM
containing 10% FCS and antibiotics
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preventing senescence or also have a role in allowing later
stages of anoikis resistance, we treated N-RAS61K cells with
PD184352, LY294002, DPI, pifithrine or caffeine only after
senescence was induced (Supplementary Figure S8D).
Again, anoikis resistance was prevented, suggesting that the
escape from senescence is also be affected by MAPK-PI3K-
and DNA damage signaling.
In their tissue of origin, melanocytes encounter hypoxic
conditions. We therefore performed a comparative analysis of
N-RAS61K-induced anoikis resistance and gene regulation
under normoxic (20% O2) and hypoxic (1% O2) conditions.
Importantly, N-RAS61K was also able to trigger OIS in hypoxia
(Supplementary Figure S9). Similarly, differentiation genes
were downregulated (Figure 7d) and the stemness marker
Pdpn as well as the neuronal marker Nefl were strongly
upregulated under hypoxic conditions. The cells were also
able to undergo anoikis resistance, albeit at lower efficiency
compared with N-RAS61K cells kept under normoxic conditions
(Figure 7c). To check whether continuous N-RAS61K signaling is
only required for the entry into senescence or whether it also
affects senescence escape, we additionally investigated
the effect of doxycycline withdrawal (thereby switching off
N-RAS61K). Under normoxic and hypoxic conditions, continuous
N-RAS61K signaling was required even after senescence entry to
allow all the features of anoikis resistance (Figures 7c–f).
Discussion
Despite the fact that premalignant tissue often displays
features of senescence, senescence is generally considered
as a tumor-suppressive mechanism, which either stalls the
tumorigenesis of premalignant cells (in case of OIS) or blocks
the progression of established tumors (in case of therapy-
induced senescence (TIS) of tumor cells). It was recently
shown that TIS is induced by a combination of IFN-γ and
TNF, which leads to impressive control of tumor growth.34
Figure 6 OIS is required for the pluripotent phenotype. (a) Phase-contrast (PH) images of unstained Hmhi cells after 14, 21 and 35 days of EGF treatment (100 ng/ml) and
brightfield images of SA-β-galactosidase-stained (β-Gal) Hmhi cells after 14 days of EGF treatment. (b) Nanog-driven GFP expression (GFP) in Hmhi and Hmhi-AR cells,
transiently transfected with the PL-SIN-EOS-S(4+)-eGFP vector. Scale bars, 100 μm. (c) Phase-contrast images of melan-a cells cultivated for 28 days without any additives (− )
or in the presence of TPA. Scale bars, 100 μm. (d) N-RAS61K cells were cultivated for 28 days in the presence of doxycycline (Dox), whereas melan-a cells were kept in media with
or without TPA. Upon 28 days of treatment, supernatant was transferred to a new 6-well plate, which was incubated for 24 h to allow cells to re-attach, followed by a 2% crystal
violet staining. (e) Left panel: Real-time PCR analysis of Tyrp1, Dct andMlana from melan-a cells cultivated for 28 days in the absence or presence of TPA, respectively. (e) Right
panel: RT-PCR analysis of Nanog, Spo11 (40 cycles each) and Pdpn (33 cycles) expression of melan-a cells starved for 28 days or treated with TPA, respectively. Dox-treated
N-RAS61K cells, also harvested after 28 days, served as a positive control. Hprt was used as a reference. *Po0.05
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However, the idea that senescence exclusively operates as
tumor-suppressive mechanism was previously challenged by
the observation that, in their niche, senescent cells secrete
factors that provide autocrine inhibitory signals, but also
stimulate neighboring premalignant cells or cause low levels of
tumor-promoting inflammation.35,36 Furthermore, senescent
cells harbor epigenetic markers, which are also found in
cancer.37 Here we provide experimental evidence that OIS
can be overcome on the cellular level and describe the
generation of highly tumorigenic melanoma cells, character-
ized by dedifferentiation and stem-like features, from senes-
cent, multinuclear pigment cells.
The accumulation of bi- and multinuclear cells is a
common feature of senescent cells in vitro, and DNA damage,
Figure 7 Involvement of signaling pathways in N-RAS61K-AR generation. (a) N-RAS61K cells were cultivated for 4 weeks in the presence of doxycycline (Dox) and DMSO
(ctrl.), the PI3K inhibitor LY294002 (LY, 10 μM), the antioxidant glutathione reduced ethyl ester (GRE, 1 mM), the p53 inhibitor pifithrine (Pifi, 10 μM), the MEK inhibitor PD184352
(PD, 2 μM) or the ATM inhibitor caffeine (Caf, 1 mM). All agents were added at the beginning of the experiments and medium with inhibitors was replaced twice weekly. Scale bars,
100 μm. (b) Upper image: RT-PCR analysis of NADPH oxidase isoforms Nox1 and Nox2 in response to N-RAS61K induction by doxycycline (Dox) (40 cycles). Hprt served as a
control. (b) Lower image: As in (a), but in the presence of DMSO (ctrl.) or the NADPH oxidase inhibitor diphenyl iodium salt (DPI, 500 nM). After 28 days, supernatant was
transferred to a new 6-well plate and cells were allowed to reattach for 24 h, followed by staining with 2% crystal violet solution. (c) N-RAS61K cells were kept for 4 weeks in the
absence (ctrl) or presence of doxycycline (Dox) under normoxic (20% O2) or hypoxic conditions (1% O2), respectively. One sample in each set was treated with doxycycline until
senescence was visible, then doxycycline was withdrawn for the remaining time (Dox off). Four weeks after the start of the experiment, supernatant was transferred to a new plate
and was stained with 2% crystal violet solution. The experiment was performed three times independently, and the image shows a representative staining. (d and e) Real-time
PCR analysis of Tyrp1, Dct andMlana (d) and Pdpn (e) from N-RAS61K cells as described in (c). Data are derived from two independent experiments, each performed in triplicate.
(f) RT-PCR analysis of Nefl in response to N-RAS61K induction as described in (c) (40 cycles). Hprt served as a control
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caused by oncogenic or replicative stress, often mediates
senescence.38 We observed that the development of
N-RAS61K-AR cells was prevented by inhibiting senescence
mediators such as NADPH oxidases and p53. Importantly,
cells that were specifically isolated according to their high p53
expression gave rise to N-RAS61K-AR cells, thus indicating
that senescence induction is a pre-requisite for the observed
anoikis resistance.
The PI3K and MAPK pathways are both required for the
development of anoikis-resistance. MEK inhibition of
N-RAS61K cells prevented the development of multinucleated
cells and consequently AR development. By contrast, PI3K
inhibition allowed multinucleation, but prevented anoikis
resistance, implicating a role for this pathway at later stages
of AR development and highlighting a co-operativity between
the MAPK and PI3K pathways in generating tumor-initiating
cells from senescent cells. In line with these observations,
it was recently shown that high PI3K activity, enabled by
PTEN depletion, helps to overcome BRAFV600E-induced
senescence.39
Although we have observed this phenomenon in our
experimental setting in vitro and clinical confirmation is still
missing, the relevance of our findings for animal models and
human melanoma is supported by several observations from
other groups. First, mice with lung-specific expression of
oncogenic RAS first develop senescent pre-malignant lung
adenomas, which only later develop into adenocarcinomas.6
As all affected lung cells express oncogenic RAS, and this
induces senescence, the tumorigenic process is likely initiated
after the induction of senescence. Second, staining of the
senescence mediator and DNA damage marker p53 is
retained in human melanoma with a history of high cumulative
sun exposure, and is even associated with higher Breslow
thickness,40 suggesting residual pro-senescent signaling in
melanoma and its compatibility with tumor maintenance.
Finally, polyploid cells, which we identified as a source for
the malignant offspring, are not only found in melanoma, but
also inmelanocytic nevi, as shown by us and others,41,42 and a
significant proportion of melanomas arise from pre-existing
nevi.43,44 In lentigo maligna (LM), also called melanoma
in situ, multinucleated ‘star burst cells’ are present in up to 85%
of patient samples.15 LM mainly occurs in chronically sun-
damaged skin and is associated with UV light exposure aswell
as p53 positivity,40,45 suggesting a causal relationship
between UV-induced DNA damage, which is a strong
senescence trigger, and the appearance of starburst cells.
In general, multinucleated or polyploid cells are at increased
risk of becoming cancerous through a combination of genomic
instability that facilitates the appearance of further mutations46
and aberrant gene expression owing to the presence of
multiple copies of many genes. Interestingly, irradiated cells of
different origin displayed a behavior comparable to our
observations, which was termed ‘neosis’.47 Here, the neotic
cells also adapted a transformed phenotype. The ‘budding’ or
‘neotic’ behavior strongly resembles the process of ‘depoly-
ploidisation’ by asymmetric division, which was recently
described for tetra- or polyploid tumor cells. Such cancer cells
can undergo a ploidy cycle where aneuploid cells give rise to
para-diploid cells, thereby re-aligning to normal cell-cycle
regulation and reducing the risk of lethal accumulation of DNA
damage.48,49 A shared phenomenon is the upregulation of
meiotic genes such as Spo11, which is associated with
depolyploidisation. This upregulation might reveal a functional
parallel between asexual ploidy reduction, for example,
occurring in cancer, and sexual ploidy reduction, occurring
during meiosis.50 Importantly, depolyploidization was also
described to go along with increased levels ofOCT4, NANOG
and SOX2.47 Stem cell-like features have also been noted in
the progeny of polyploid giant cancer cells,51 suggesting that
multinucleated senescent cells and polyploid cancer cells
share crucial pro-tumorigenic features.
Our data illustrate a mode of overcoming senescence that
takes place in response to naturally occurring oncogenes such
as the melanoma oncogene N-RAS61K. This process is
accompanied by the loss of melanocyte markers and by the
increase of neuronal- and neural crest-like expression
patterns. Importantly, the cells display features of highly
dedifferentiated cells, such as a high nuclear-cytoplasmic
ratio and increased expression of the transcription factor
NANOG, which might explain their aggressive growth and
early metastasis in vivo. Similar to our observations in
melanocytes, transformed pigmented melanoma cells also
show the tendency to express enhanced levels of stem cell
markers or markers of melanoma initiating cells when they are
forced into dedifferentiation,25,52 thus suggesting a common
epigenetic and pro-tumorigenic program that can not only
be triggered in transformed melanoma cells, but also in
senescent melanocytes.
Materials and Methods
Cell culture. N-RAS61K and Hmhi-cells as well as melan-a cells were
presviously described and cultivated as reported earlier.11,53 In addition to these
described pTRE2-hyg-N-RAS61K cells, which were derived from one cell
clone, another inducible N-RAS61K transgenic cell line was generated. We used
the vector pSB-ET-iE (M. Gessler, Dept. of Developmental Biochemistry, University
of Wurzburg), which allows integration of N-RAS61K by sleeping beauty-mediated
transposition. Here, the responsive T6 promoter drives expression of N-RAS61K
and EGFP, the latter being separated from the NRAS gene by an IRES site.
After transposition, these cells were selected with 1 μg/ml puromycin for 2 weeks,
and the oligoclonal cell population was used for further experiments. N-RAS61K
was cloned into the vector using NheI/AfeI restriction enzyme sites. For long-term
treatment, cells were cultured in starving medium (Dulbecco’s Modified
Eagle’s Medium with 10% dialyzed, fetal calf serum (Gibco/Invitrogen, Karlsruhe,
Germany) for 3 days before the assay. Induction of the oncogene was generally
done using 1 μg/ml doxycycline for the indicated timespans, if not indicated
otherwise. In general, medium containing doxycycline was changed 2–3 times
per week.
The vectors pBabe-puro-H2-eGFP and pBabe-MN [EF1a-red membrane and
green nucleus]-2APuro were delivered into the cells by retroviral infection according
to standard protocols. pBabe-puro-H2-eGFP contains a fusion protein of histone 2B
and enhanced GFP, thus leading to green fluorescence of the nucleus. pBabe-MN
[EF1a-red membrane and green nucleus]-2APuro vector expresses a fusion product
of the membrane targeting sequence MGCIKSKRKDNLNDDE with mCherry, followed
by a T2A site and a fusion protein of histone 2B with eGFP.
Normal human embryonic melanocytes (NHEM) cells were transfected with
pCDH-CMV-NRAS61K-EF1-copGFP and were cultivated in melanocyte growth
medium (Promocell, Heidelberg, Germany). pGreenFire-p53 (Biocat, Heidelberg,
Germany) was delivered into N-RAS61K cells by lipofection according to standard
protocols. Where indicated, cells were treated with LY294001, GDC-0941, PD184352
(Selleckchem, Houston, TX, USA), glutathione reduced ethyl ester, pifithrine, caffeine
or diphenyliodonium chloride (Sigma-Aldrich, Taufkirchen, Germany).
RNA isolation and real-time PCR. RNA isolation was performed with TrIR
solution (ABGene, Hamburg, Germany) from at least two independent biological
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replicates. Whole RNA was reversely transcribed using the RevertAidTM First
Strand cDNA Synthesis Kit (Fermentas, Leon-Rot, Germany). Fluorescence-based
quantitative real-time PCR was performed using the iCycler (Bio-Rad, Munich,
Germany), and for each gene, three independent real-time PCRs were performed
with cDNA from each biological replicate. The sequence of oligonucleotides used
can be found in the Supplementary information (Supplementary Table 3). Gene
expression was normalized to hypoxanthine-guanine phosphoribosyltransferase.
Relative expression levels were calculated applying REST software.
Protein blot. Cells were lysed in HEPES-based lysis buffer (20 mM HEPES
(pH 7.8), 500 mM NaCl, 5 mM MgCl2, 5 mM KCl, 0.1% deoxycholate, 0.5%
Nonidet-P40, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 200 mM Na3VO4, 1 mM
phenylmethanesulphonylfluoride and 100 mM NaF). In all, 30–50 μg of protein
lysate was separated by SDS-PAGE and was transferred onto nitrocellulose
membranes. Anti-β-actin (C4), NRAS (F155) and p21 (N20) antibodies were
purchased from Santa Cruz Biotechnology (Heidelberg, Germany). P19-ARF
antibody (#ab80) was from Abcam (Cambridge, UK). Antibodies directed against
P-ERK1/2 (Thr202/Tyr204, #9101), P-AKT (Ser473, #4060), P-p53 (Ser18, #9284)
and γ-H2AX (#2577) were purchased from Cell Signaling Technologies (Danvers,
MA, USA). Anti-vinculin antibody (#V-9131) was acquired from Sigma-Aldrich
(Heidelberg, Germany). P53 antibody was generated from hybridoma supernatant
and was supplied by T. Stiewe (Institute of Molecular Biology and Tumor Research,
University of Marburg, Germany). Generally, the presented protein blots are
representative for 2–3 independent experiments.
SA-β-Gal staining. Cells were washed with phosphate-buffered saline (PBS;
pH 7.2) and fixed with 3.7% formaldehyde in PBS for 5 min at room temperature.
After washing, they were stained in the dark for 12 h at 37 °C (using 1 mg/ml X-Gal,
40 mM citric acid/sodium phosphate buffer (pH 6.0), 5 mM potassium ferricyanide,
5 mM potassium ferrocyanide, 150 mM NaCl and 2 mM MgCl2). Cells were then
washed with PBS and were examined by light microscopy.
Soft agar growth. One milliliter of 1.2% agar was mixed with 1 ml 2 × DMEM
supplemented with 10% FCS and plated onto 6-well plates. Upon polymerization,
the solid agar was overlain with an equal amount of soft agar mix (0.6% agar)
containing 4 × 104 cells per well. The polymerized soft agar was overlain with 100 μl
of D10 medium every second day.
In vivo growth. Nude mice (NMRI, Harlan strain) were subcutaneously
injected with 2.5 × 106 melan-a, N-RAS61R or N-RAS61R-AR cells per flank.
Where indicated, 2 mg/ml doxycycline (Sigma-Aldrich) dissolved in 10% saccharose
solution was supplied ad libitum by administration to the drinking water.
After 4 weeks, N-RAS61R-AR mice were killed due to considerable tumor load. In
all other mice, growth of injected cells was monitored for 10 weeks after injection
before killing the mice. All experiments were in accordance with the institution's
guidelines.
Immunohistochemistry. Ki67 and phospho-Histone H3-S10 staining was
perfomed using SP6 (Neomarkers, Fremont, CA, USA) and 06-570 (Upstate/
Milipore, Billerica, MA, USA) as previously described.54 Alexa-Fluor conjugated anti-
rabbit secondary antibodies (Invitrogen/Life Technologies, Darmstadt, Germany)
were used for detection and tissues were counterstained with Hoechst 33342
(Invitrogen).
Paraffine-embedded material of human nevi was subjected to routine
histopathological methods. For determination of multinucleated cells, slides were
stained with hematoxyline-eosine and in addition with PAS reaction (period acid Schiff
reaction), as recommended by the manufacturer (Sigma-Aldrich).
Microarray. NRAS61K cells were treated for 6, 14 or 28 days with 1 μg/ml
doxycycline (Sigma-Aldrich) and NRAS61K-AR cells underwent the same treatment
for 10 days before being harvested. RNA was isolated using the miRNeasy Kit
(Qiagen, Hilden, Germany), and analyzed using the Affymetrix Gene Chip Mouse
Genome 430 2.0. All data were analyzed using different R packages from the
Bioconductor project (www.bioconductor.org). Obtained data are deposited at http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27010.
Statistic analysis. Generally, all graphs depict the mean values of at least
three independent experiments, standard deviations are indicated. Student's t-test
(two-tailed, paired) revealed statistical significance highlighted by asterisks
(*Po0.05; **Po0.01, ***Po0.001).
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